How India Exports Terbutaline to the World

In the United States, terbutaline is approved for the treatment of bronchospasm associated with asthma, bronchitis, and emphysema. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for terbutaline sulfate tablets and injections, indicating a well-established generic market. As of March 2026, there are no active import alerts related to terbutaline, suggesting compliance with FDA standards among exporters. However, in February 2011, the FDA issued a Drug Safety Communication warning against the use of terbutaline for prolonged treatment of preterm labor due to potential serious maternal heart problems and death. This led to the addition of a Boxed Warning and Contraindication to the terbutaline injection label.

Given the competitive landscape, Indian exporters must ensure strict adherence to FDA regulations, including Good Manufacturing Practices (GMP) and accurate labeling, to maintain and expand their market share in the U.S.

In the European Union and the United Kingdom, terbutaline is authorized for the treatment of asthma and other respiratory conditions. The European Medicines Agency (EMA) has conducted periodic safety assessments of terbutaline. In October 2022, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information to emphasize the risks associated with overuse, including deteriorating asthma control and life-threatening exacerbations. (ema.europa.eu)

Additionally, in October 2013, the EMA restricted the use of short-acting beta-agonists, including terbutaline, for obstetric indications due to safety concerns. (ema.europa.eu) Compliance with EU GMP requirements is mandatory for market authorization, necessitating that Indian exporters align their manufacturing processes with these standards to ensure continued access to these markets.

Terbutaline is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, underscoring its importance in global health. (who.int) The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, terbutaline is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for terbutaline formulations to ensure affordability; however, the exact ceiling price and date of implementation should be verified from the latest NPPA notifications. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

Terbutaline's primary patents have expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive environment necessitates that Indian exporters focus on maintaining high-quality standards and cost-effective production to remain competitive in both domestic and international markets.

In October 2022, the EMA's PRAC recommended updates to terbutaline product information to highlight the risks associated with overuse, including deteriorating asthma control and life-threatening exacerbations. (ema.europa.eu)

In September 2025, the WHO published the 24th edition of its Model List of Essential Medicines, reaffirming terbutaline's status as an essential medicine for respiratory conditions. (who.int)

These developments underscore the importance of continuous monitoring of regulatory changes and adherence to international standards to ensure market access and patient safety.

Terbutaline, a bronchodilator used in the treatment of asthma and bronchospasm, relies on Active Pharmaceutical Ingredients (APIs) that are predominantly manufactured in India. However, the production of these APIs is heavily dependent on Key Starting Materials (KSMs) sourced from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting a significant supply chain vulnerability.

This dependency has been exposed during instances where Chinese regulatory actions led to the shutdown of API manufacturers failing to meet pollution norms, causing supply disruptions and cost escalations. Such events underscore the risks associated with over-reliance on a single country for critical raw materials.

Our proprietary trade data indicates that the top five exporters of Terbutaline from India account for 76.9% of the total export value, with UMAVIDA PHARMA PRIVATE LIMITED alone contributing 63.5%. This high supplier concentration poses a significant risk, as any disruption affecting these key players could severely impact global supply chains.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing import dependence on critical pharmaceutical ingredients. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, marking a step towards self-reliance.

Geopolitical tensions and shipping disruptions have further exacerbated supply chain vulnerabilities. Incidents in critical maritime routes such as the Red Sea and the Strait of Hormuz have led to increased freight costs and delays. Additionally, U.S.-China trade tensions have introduced uncertainties in the availability and pricing of APIs and KSMs. The FDA has acknowledged that drug shortages can occur due to manufacturing and quality problems, delays, and discontinuations, emphasizing the need for proactive supply chain management.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical raw materials to decrease reliance on imports.

• Strengthen Regulatory Compliance: Ensure all suppliers adhere to stringent environmental and quality standards to prevent disruptions due to regulatory actions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on supply chains.

• Develop Contingency Plans: Create and regularly update comprehensive risk management strategies to address potential supply chain disruptions.

RISK_LEVEL: HIGH